If you haven't already done so, please review the benefits of IMACS membership All required fields have the word (Required) after the label. Optional information is used to facilitate use of information on IMACS members. Demographics Applicant Information Membership Type Membership Type (Required): Associate Associate Members are trainee members (students, fellows), research assistants, or members of non-profit or for-profit organizations. Full Full Members may participate in IMACS committees (voted positions), and participate in voting on IMACS committee members and policies. First Name (Required) Last Name (Required) Degree(s) (PhD, MD, ...) (Required) Professional Role (Required) Please Choose One Health Professional Scientist Please Choose One Clinical Research Professional Clinical Trainee Health Professional Patient Support Group Pharmaceutical-Biotech Research Trainee Scientist Sub Role Please Choose One Board Member Clinical Research Coordinator Director Fellow Graduate Student Medical Student Post-Baccalaureate Trainee Post-Doctoral Research Fellow Research Assistant/Management Resident Scientist N/A Speciality (Required) Please select at least one option. If multiple options are applicable, hold the "CTRL" key down and select all options that apply Dentist Dermatology Immunology Internal Medicine Neurology Neuromuscular Obstetrics and Gynecology Occupational Therapy Oncology Pathology Pediatric Rheumatology Pediatrics Pharmacy Physical Therapy Physician Assistant Pulmonary and Critical Care Medicine Radiology Research Nurse Rheumatology N/A Other Biological Sciences Biostatistics Cardiology Dermatology Hematology-Oncology Immunology Internal Medicine Microbiology Neurology Neuromuscular Occupational Therapy Oral and Maxillofacial Surgery Orthopedic Surgery Pathology Pediatric Neurology Pediatric Rheumatology Pediatrics Physical Medicine and Rehabilitation Physical Therapy Physiology Pulmonary and Critical Care Medicine Rheumatology Speech Language Pathology Sports Medicine Genetics N/A Other Other Specialty: Specify Primary Email (Required) This email address will be used as the primary communication point for IMACS correspondence as well as logging in to IMACS. This email address should be your work email. Secondary Email (Required) This email address will be used for correspondence regarding password reset/recovery in the event that your primary email address is no longer accessible. This email address is only visible to you and the site administrator. Clinical or Research Training Completed DatePlease add date to be part of the mentorship program Affiliation Information Affiliation (check all that apply) Affiliation (check all that apply): Hospital Private Clinic University Government Non-profit Industry Other, please specify: Primary Affiliation Address Affiliation Name (Required) Street Address (line 1) (Required) Street Address (line 2) City (Required) Country (Required) Please Choose a Country United States Afganistan Albania Algeria American Samoa Andorra Angola Anguila Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean territory Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire (Ivory Coast) Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea-Bissau Guinea Guyana Haiti Heard and McDonald Islands Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Liechtenstein Lithuania Luxembourg Macau Macedonia Madagascar Malaysia Malawi Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovak Republic Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Togo Tokelau Tonga Trinidad and Tobego Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands (British) Virgin Islands (US) Wallis and Futuna Islands Western Sahara Yemen Yugoslavia Zaire Zambia Zimbabwe State/Province (Required) Please Choose a State or Province State/Province (if applicable) Postal Code (Required) Telephone (Required) Fax Web Address Optional Information Please complete the optional information below to facilitate communication among IMACS members. Myositis Research Are you interested in Myositis research? Are you interested in Myositis research? Yes No What areas of myositis research interest you? Select all that apply: What areas of myositis research interest you? Select all that apply: Animal models Clinical presentation and manifestations Clinical trials Diagnostic/Classification/Subclassification Criteria Disease assessment Environmental factors / myotoxins Epidemiology Immunology Muscle molecular biology, biochemistry or function Muscle structure or ultrastructure Genetic risk factors Natural history of disease Outcomes research Pathogenesis of disease Pathology Pre-clinical therapeutic development Therapy / prognosis Other, please specify: Myositis Patients Are you responsible for the clinical area of myositis patients? Are you responsible for the clinical area of myositis patients? Yes No What types of myositis patients are under your care? What types of myositis patients are under your care? Adult Myositis Juvenile Myositis Both Please select all clinical forms of myositis that you care for from the following: Please select all clinical forms of myositis that you care for from the following: Dermatomyositis Juvenile Dermatomyositis Polymyositis Inclusion body myositis Anti-Synthetase Syndrome Immune-Mediated Necrotizing Myopathy Other, please specify: Clinical Trials Readiness Are you interested in enrolling patients and participating in myositis clinical trials? Are you interested in enrolling patients and participating in myositis clinical trials? Yes No What are the number and types of myositis patients you take care of? What are the number and types of myositis patients you take care of? Please select a value for each type Dermatomyositis Select one 0 Less than 10 10-20 Greater than 20 Juvenile Dermatomyositis Select one 0 Less than 10 10-20 Greater than 20 Polymyositis Select one 0 Less than 10 10-20 Greater than 20 Inclusion Body Myositis Select one 0 Less than 10 10-20 Greater than 20 Anti-Synthetase Syndrome Select one 0 Less than 10 10-20 Greater than 20 Immune-Mediated Necrotizing Myopathy Select one 0 Less than 10 10-20 Greater than 20 Which Trials? Please provide detailed information including: Trial Name, Treatment Name, CTC ID#, etc. 2000 characters remaining In the last 10 years, how many myositis clinical trials have you/has your center participated in? In the last 10 years, how many myositis clinical trials have you/has your center participated in? Please select one None 1-3 4-6 7-10 >10 Is your center able to participate in multi-center placebo-controlled efficacy studies? Is your center able to participate in multi-center placebo-controlled efficacy studies? Yes No Does your center have both a clinical and separate safety assessor? Does your center have both a clinical and separate safety assessor? Yes No Does your center have a research coordinator experienced in myositis? Does your center have a research coordinator experienced in myositis? Yes No Does your center have a dedicated physical therapist to test strength? Does your center have a dedicated physical therapist to test strength? Yes No Is your center able to process research blood specimens? Is your center able to process research blood specimens? Yes No Is your center able to process research muscle biopsies? Is your center able to process research muscle biopsies? Yes No Does your center have access to thigh MRI? Does your center have access to thigh MRI? Yes No Does your center have access to whole body MRI? Does your center have access to whole body MRI? Yes No Scientific Interest Groups Are you interested in joining any of the following Scientific Interest Groups? Are you interested in joining any of the following Scientific Interest Groups? Calcinosis in Juvenile and Adult Dermatomyositis × Calcinosis in Juvenile and Adult Dermatomyositis Calcinosis can be a devastating complication in juvenile and adult dermatomyositis leading to significant morbidity. Since there are no effective therapies for calcinosis, the development of novel therapeutic agents is desperately needed. The aims of this group are to advance our understanding of the etiology, pathogenesis, assessment, and treatment of calcinosis in juvenile and adult dermatomyositis. Extension of SHARE consensus for management of JDM × Extension of SHARE consensus for management of JDM The European Initiative, called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE), developed recommendations to optimize and disseminate diagnostic and management regimens in Europe, for several conditions, including juvenile dermatomyositis (JDM). The aims of these recommendations were to develop the ‘best practices’ for the treatment for these conditions, to produce a standard of care or ‘best practices’ for patient care throughout Europe. The IMACS SHARE Scientific Interest Group was formed to review and augment the JDM SHARE recommendations and consider their applicability and feasibility internationally, including for patients outside of Europe. Inclusion Body Myositis × Inclusion Body Myositis Sporadic Inclusion body myositis (IBM) is a gradually progressive idiopathic inflammatory myopathy, which typically leads to severe disability, including difficulty using hands, impaired mobility, and dysphagia. There is currently no proven treatment for patients with IBM. Lack of validated outcome measures and objective biomarkers are major limitations in IBM clinical trials. This group will focus on examining outcome measures in IBM in order to optimize them for future clinical trials. International Classification of Diseases (ICD) × International Classification of Diseases (ICD) The proper billing and coding of a disease is important for the management of patients, and for research. This group is working to optimize the coding systems that are of importance to the idiopathic inflammatory myopathies. We have previously received ICD-10-CM approval and implementation for codes for dermatomyositis and dermatomyositis without myopathy, and are working on additional ICD coding issues. Myositis Autoantibodies × Myositis Autoantibodies The discovery of new myositis autoantibodies that identify distinct patterns of disease within the myositis spectrum has been a major advance in the field in recent years. The availability of reliable assays to measure myositis autoantibodies in routine clinical practice is an ongoing unmet need. This group will promote knowledge to take full advantage of the clinical utility of myositis autoantibody testing, and provide a forum for interchange of ideas and collaboration to identify important areas for future research. Myositis Genetics (MYOGEN) × Myositis Genetics (MYOGEN) Several genetic risk factors have been identified in myositis, including genetic variants that discriminate between clinically and serologically defined subgroups. Some of these genetic variants overlap with those reported in other autoimmune disorders. Increased knowledge of genetic risk factors may increase understanding of the etiology and pathogenesis of myositis, enabling more stratified medicine. This group aims to identify genetic risk and protective factors for myositis, including those relating to specific phenotypes, environmental exposures, and ethnic groups. Outcome Assessment × Outcome Assessment IMACS has a long history of working to develop and validate disease activity and damage assessment tools and myositis response criteria. The objectives of this SIG will be to continue work on development and validation of new assessment measures in myositis, including those utilizing novel technologies. Rehabilitation and Exercise Group × Rehabilitation and Exercise Group This group is devoted to studying the effect of exercise therapy and rehabilitation on the disease and vice versa in juvenile and adult myositis. To this end, the group has focused on developing and validating measures for fatigue and endurance, muscle strength testing, and functional testing for juvenile and adult myositis that can be used as endpoints in such studies. Currently, a large focus of the group’s work is to develop International Guidelines on Exercise for all forms of myositis. Telemedicine in Myositis × Telemedicine in Myositis Telemedicine can play an important role in the care and support of people living with IIM. Visiting a specialist clinic often involves travelling long distances, a journey which can be made more difficult by muscle weakness, fatigue, and other disability. The COVID pandemic, and the reduction in face-to-face activity at many centers, has drawn this into even sharper focus. However, the opportunities of telemedicine also bring potential risks which need to be considered. The aim of this group is to agree best practice guidelines for conducting telemedicine consultations in IIM clinics and support the increased use of telemedicine in the routine care of our patients. Curriculum Vitae or NIH BioSketch Please have your CV or NIH BioSketch updated before you begin the membership application. Your CV or NIH BioSketch is required for membership approval as a FULL or ASSOCIATE member of IMACS. Please attach your CV or NIH BioSketch in one of the following file formats: Adobe PDF document (filename.pdf) Word document (filename.doc or filename.docx) Rich Text Format (filename.rtf) CV or NIH BioSketch: Profile Photo (.jpg, .png, .gif) Image File: × Form Submission Error The form has errors, please check all orange highlighted fields and try again.